A cagrilintide reconstitution chart provides precise liquid diluent volumes required to achieve target concentrations from lyophilized research vials. By referencing exact mass-to-volume ratios, laboratory researchers can accurately prepare cagrilintide for in vitro assays, receptor binding studies, and automated analytical platforms while maintaining peptide stability and compound integrity.
A cagrilintide reconstitution chart provides precise liquid diluent volumes required to achieve target concentrations from lyophilized research vials. By referencing exact mass-to-volume ratios, laboratory researchers can accurately prepare cagrilintide for in vitro assays, receptor binding studies, and automated analytical platforms while maintaining peptide stability and compound integrity.
A cagrilintide reconstitution chart simplifies laboratory workflow by calculating the final concentration (mg/mL or mcg/uL) based on the total lyophilized peptide mass in the vial and the volume of solvent added. Because accurate quantitative analysis relies on exact molar or mass concentrations, preparing stock solutions requires strict adherence to volumetric principles. The standard formula applied in these calculations is Concentration (C) = Mass (m) / Volume (V).
Below is a standard laboratory reference table for reconstituting common mass quantities of lyophilized cagrilintide using standard laboratory diluents such as bacteriostatic water (0.9% benzyl alcohol) or sterile 0.9% sodium chloride solution:
For a 2 mg vial of lyophilized cagrilintide: - Adding 1.0 mL diluent yields a final concentration of 2.0 mg/mL (2.0 mcg/uL). - Adding 2.0 mL diluent yields a final concentration of 1.0 mg/mL (1.0 mcg/uL). - Adding 4.0 mL diluent yields a final concentration of 0.5 mg/mL (0.5 mcg/uL).
For a 5 mg vial of lyophilized cagrilintide: - Adding 1.0 mL diluent yields a final concentration of 5.0 mg/mL (5.0 mcg/uL). - Adding 2.5 mL diluent yields a final concentration of 2.0 mg/mL (2.0 mcg/uL). - Adding 5.0 mL diluent yields a final concentration of 1.0 mg/mL (1.0 mcg/uL).
For a 10 mg vial of lyophilized cagrilintide: - Adding 2.0 mL diluent yields a final concentration of 5.0 mg/mL (5.0 mcg/uL). - Adding 5.0 mL diluent yields a final concentration of 2.0 mg/mL (2.0 mcg/uL). - Adding 10.0 mL diluent yields a final concentration of 1.0 mg/mL (1.0 mcg/uL).
When planning assays across our all peptides catalog, researchers must factor in both the dead volume of liquid handling equipment and the specific solubility limits of long-acting acylated peptides. Precise concentration modeling ensures high reproducibility across experimental replicates.
Cagrilintide is a lipidated, long-acting dual amylin and calcitonin receptor agonist (DACRA). Due to its hydrophobic fatty acid side chain, its dissolution kinetics differ from simple un-acylated hydrophilic peptides. Choosing the appropriate reconstituting vehicle is critical to achieving a clear, aggregate-free solution without altering the secondary structure.
Bacteriostatic water containing 0.9% benzyl alcohol is the standard solvent for multi-use research vials, as the antimicrobial agent prevents bacterial proliferation during repeated sampling over standard experimental timeframes. For short-term single-use assays or cell culture systems where benzyl alcohol may induce cytotoxicity, sterile 0.9% sodium chloride (saline) or sterile water for injection (SWFI) is preferred.
Preclinical studies indicate that lipidated peptides may exhibit altered solubility at physiological pH ranges or high concentrations. If minor opalescence occurs during initial solvation, gentle temperature equilibration to room temperature (20°C–25°C) and mild rotational mixing usually resolves the suspension into a transparent liquid. Avoid high-shear mechanical agitation such as aggressive vortexing, which can introduce air bubbles and denature sensitive peptide chains. Additional technical data can be explored in our research library.
To ensure precise concentration and prevent contamination during reconstitution, laboratory personnel should follow standardized aseptic procedures within a laminar flow hood or clean bench setup.
Step 1: Sanitize the vial stopper. Remove the flip-off cap from the lyophilized cagrilintide vial and swab the rubber septum with a 70% isopropyl alcohol wipe. Allow the alcohol to air-dry completely to prevent solvent interaction with the peptide mass.
Step 2: Prepare the diluent syringe. Using a sterile laboratory syringe fitted with an appropriate gauge needle (e.g., 21G–25G), draw up the exact volume of diluent indicated by your experimental cagrilintide reconstitution chart.
Step 3: Introduce diluent along the glass wall. Insert the needle through the center of the rubber septum at a 45-degree angle. Direct the stream of diluent down the inner glass wall of the vial rather than shooting it directly onto the lyophilized cake. This technique minimizes mechanical shear stress and prevents excessive foaming.
Step 4: Equalize internal pressure. If the vial is sealed under partial vacuum, allow the vacuum to draw the diluent into the vial, then equalize the pressure by drawing an equivalent volume of air back into the syringe before removing the needle.
Step 5: Complete dissolution. Roll the vial gently between your palms or place it on a low-speed orbital shaker for 2–5 minutes. Inspect the solution under bright light to verify total clarity before drawing aliquots for analytical testing. Consult our cagrilintide solubility and stability guide for troubleshooting incomplete dissolution.
Lyophilized cagrilintide maintains maximum long-term stability when stored at -20°C to -80°C in a temperature-monitored freezer, protected from moisture and light exposure. Under these conditions, unopened lyophilized vials remain stable for up to 24 months from the date of manufacture.
Once reconstituted with bacteriostatic water, the solution should be stored at 2°C to 8°C (refrigerated) and used within 28 days. If reconstituted using sterile water without preservatives, the liquid stock must be used immediately or frozen in single-use working aliquots to prevent microbial contamination.
To prevent degradation caused by freeze-thaw cycles, researchers working with large reconstituted volumes should divide the liquid into small single-use polypropylene microtubes before freezing at -80°C. Repeated freezing and thawing breaks peptide bonds and promotes hydrophobic aggregation, significantly reducing active concentration over time.
In metabolic and endocrine research, cagrilintide is frequently evaluated alongside or in combination with incretin mimetics due to its distinct, non-incretin mechanism of action. While incretin analogs target the GLP-1 and GIP signaling pathways, cagrilintide selectively activates amylin receptors (AMYR1, AMYR2, AMYR3) and calcitonin receptors (CTR).
When comparing laboratory reconstitution profiles across these classes, researchers should note differences in molecular weight, acylation structures, and baseline solubility:
1. Cagrilintide: A non-selective dual amylin/calcitonin receptor agonist modified with a fatty acid diacid chain to extend plasma half-life in animal models. Requires careful solvation due to lipidated hydrophobic domains.
2. Semaglutide: A mono-GLP-1 receptor agonist featuring a C18 fatty acid side chain. Shares similar acylation characteristics with cagrilintide but exhibits different iso-electric points and buffer pH stability windows.
3. Tirzepatide: A dual GIP/GLP-1 receptor agonist containing a C20 fatty diacid chain. Due to its larger peptide sequence (39 amino acids), reconstitution times may vary slightly compared to cagrilintide.
4. Retatrutide: A triple GIP/GLP-1/glucagon receptor agonist utilized in advanced multi-pathway preclinical trials.
Comparative in vitro binding assays demonstrate that co-incubating an amylin agonist like cagrilintide alongside GLP-1 analogs allows researchers to evaluate synergistic cellular signaling without cross-occupancy of primary receptor targets. Learn more about class comparisons in our amylin analogs overview.
Precise reconstitution calculations rely entirely on the purity and mass accuracy of the starting lyophilized compound. PX1 Research enforces strict quality control specifications for every batch of research peptides produced in our US-based manufacturing facilities.
Every production lot undergoes rigorous identity and purity testing via high-performance liquid chromatography (RP-HPLC) and liquid chromatography-mass spectrometry (LC-MS) at an independent ISO 17025 accredited testing laboratory. We guarantee a minimum peptide purity of 99.0%, ensuring that experimental results are not compromised by truncated sequences or residual synthesis reagents.
Furthermore, all PX1 Research products undergo bacterial endotoxin testing via Chromogenic LAL assay, verifying endotoxin levels remain below strictly controlled threshold limits (<0.01 EU/mg). Products are shipped direct from our fulfillment centers in California and Arizona with same-day dispatch for orders placed Monday through Friday. Laboratories requiring large-scale compound quantities for ongoing research protocols can apply for a dedicated wholesale account to access bulk lot allocations and batch-specific analytical packages.
What is a cagrilintide reconstitution chart?
A cagrilintide reconstitution chart is a volumetric calculation matrix that maps out the exact volume of diluent (such as bacteriostatic water) needed to reach a specific concentration (e.g., mg/mL or mcg/uL) based on the total mass of lyophilized cagrilintide in a vial.
How much bacteriostatic water do you mix with cagrilintide?
The volume of bacteriostatic water depends on your target concentration. For example, adding 2.0 mL of bacteriostatic water to a 5 mg lyophilized vial of cagrilintide creates a stock solution of 2.5 mg/mL, whereas adding 2.5 mL yields a 2.0 mg/mL concentration.
What diluent should be used for reconstituting cagrilintide for in vitro research?
Bacteriostatic water (0.9% benzyl alcohol) is recommended for multi-use laboratory vials to maintain sterility. For short-term assays where preservatives might interfere with cellular viability, sterile 0.9% sodium chloride or sterile water for injection (SWFI) is preferred.
How should reconstituted cagrilintide be stored in the lab?
Reconstituted cagrilintide solutions prepared with bacteriostatic water should be stored at 2°C to 8°C (refrigerated) for up to 28 days. For long-term storage, single-use aliquots should be frozen at -80°C to minimize degradation and avoid repeated freeze-thaw cycles.
Why is cagrilintide slow to dissolve during reconstitution?
Cagrilintide contains a hydrophobic fatty acid diacid modification designed to extend half-life. This lipidated structure can reduce initial dissolution rates compared to non-acylated peptides. Rolling the vial gently at room temperature will help clear the solution.
Can you vortex cagrilintide to speed up reconstitution?
Vortexing or vigorous shaking is not recommended. Mechanical shear stress can induce peptide denaturation, foaming, and aggregation. Gentle manual rotation or low-speed orbital swirling is the preferred method.
What is the purity standard for PX1 Research cagrilintide?
PX1 Research supplies cagrilintide verified at ≥99.0% purity by independent RP-HPLC and mass spectrometry. Each lot is accompanied by a batch-specific Certificate of Analysis (COA) detailing purity, mass verification, and endotoxin levels.
How do you calculate concentration per unit volume after reconstitution?
Divide the total milligram mass of lyophilized peptide by the total volume of solvent added in milliliters. For instance, a 10 mg vial reconstituted with 2 mL diluent yields 10 mg / 2 mL = 5 mg/mL (or 5 mcg per microliter).
What is the molecular mechanism of cagrilintide in preclinical research?
Cagrilintide functions as a non-selective dual amylin and calcitonin receptor agonist (DACRA), activating AMYR1, AMYR2, AMYR3, and calcitonin receptors to modulate metabolic signaling, gastric emptying rates, and energy balance in animal models.
How does PX1 Research handle shipping for temperature-sensitive peptides?
PX1 Research packages compounds using protective insulated thermal barriers and ships directly from centralized facilities in California and Arizona. Orders placed Monday through Friday before cut-off ship same-day to preserve compound stability during transit.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.